P275 Platinum compounds (PLcs) added to standard adjuvant or neoadjuvant regimen of doxorubicin plus cyclophosphamide (AC), followed by weekly paclitaxel (wP) in triple negative (TN), HER 2-neu positive (HER 2+) or locally advanced breast cancer (LABC)